Novo Nordisk regains Novorapid supply capacity
After a challenging period, Novo Nordisk can once again supply fast-acting insulin product Novorapid, Dagens Pharma reports.
by mikkel aabenhus hemmingsen, translated by catherine brett
Supply chain issues concerning Novo Nordisk’s fast-acting insulin product Novorapid (insulin aspart) have been resolved, industry media Dagens Pharma reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
